Imugene (AU:IMU)
ASX:IMU
Want to see AU:IMU full AI Analyst Report?
Top Page
Imugene
(Sydney:IMU)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.11
▼(-66.67% Downside)
Action:Upgraded
Date:06/20/26
The score is primarily weighed down by weak financial performance, including sharp revenue decline, ongoing losses, and poor returns on equity, with additional pressure from negative operating cash flow indicators. Technicals are mixed but remain weak longer-term given price below the 100/200-day averages and a negative MACD. Valuation is difficult to justify with a negative P/E and no dividend yield data.
Positive Factors
Diversified immuno-oncology pipeline
Imugene’s portfolio spans multiple immuno-oncology modalities (oncolytic viruses, B‑cell activators, CAR T and engager approaches). This multi-pronged R&D strategy structurally diversifies clinical risk, increases potential partnering pathways and multiple value-inflection points over months.
Negative Factors
Sharp revenue decline
A very large revenue decline (-338.95%) is a durable structural concern: it reduces internal funding capacity, weakens negotiating leverage for partners, and heightens dependence on external financing to progress clinical programs, increasing dilution risk over the next several months.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified immuno-oncology pipeline
Imugene’s portfolio spans multiple immuno-oncology modalities (oncolytic viruses, B‑cell activators, CAR T and engager approaches). This multi-pronged R&D strategy structurally diversifies clinical risk, increases potential partnering pathways and multiple value-inflection points over months.
Read all positive factors
Imugene (IMU) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$39.50M
Dividend YieldN/A
Average Volume (3M)877.83K
Price to Earnings (P/E)―
Beta (1Y)2.14
Revenue GrowthN/A
EPS Growth62.72%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.22
Shares Outstanding415,835,050
10 Day Avg. Volume850,615
30 Day Avg. Volume877,834
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.15
Price to Sales (P/S)21.99
P/FCF Ratio-1.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.25Price Target Upside-24.24% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.1
Revenue Forecast (FY)AU$2.50M
Imugene Business Overview & Revenue Model
Company Description
Imugene Limited is an Australian clinical-stage immuno-oncology firm focused on creating innovative immunotherapies. Its core mission is to activate the immune systems of cancer patients, enabling them to effectively fight and eradicate tumors. A ...
How the Company Makes Money
Imugene does not appear to generate recurring revenue from marketed products; its primary funding has historically come from raising capital from investors (e.g., equity placements/rights issues) to finance research and clinical development. Poten...
Imugene Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.14M | 4.40M | 4.97M | 11.78M | 12.97M | 7.23M |
| Gross Profit | 2.79M | 4.40M | 4.97M | 9.57M | 10.56M | 5.27M |
| EBITDA | -58.98M | -67.42M | -147.98M | -47.42M | -48.06M | -23.72M |
| Net Income | -58.50M | -69.02M | -149.68M | -37.91M | -37.87M | -18.45M |
Balance Sheet | ||||||
| Total Assets | 67.67M | 83.59M | 151.40M | 197.06M | 147.61M | 71.81M |
| Cash, Cash Equivalents and Short-Term Investments | 14.14M | 21.94M | 94.54M | 153.15M | 99.89M | 29.49M |
| Total Debt | 5.02M | 10.65M | 2.19M | 553.47K | 673.43K | 271.03K |
| Total Liabilities | 25.80M | 38.56M | 33.14M | 7.44M | 8.90M | 6.79M |
| Stockholders Equity | 41.87M | 45.03M | 118.25M | 189.63M | 138.70M | 65.02M |
Cash Flow | ||||||
| Free Cash Flow | -59.70M | -90.03M | -108.80M | -29.78M | -30.93M | -18.58M |
| Operating Cash Flow | -62.92M | -75.57M | -101.73M | -29.78M | -30.67M | -13.13M |
| Investing Cash Flow | 2.86M | -12.70M | -7.25M | 9.63K | -414.16K | -5.48M |
| Financing Cash Flow | 40.66M | 17.37M | 49.43M | 82.98M | 101.35M | 17.99M |
Imugene Technical Analysis
Positive
0.33
Price Trends
0.11
Positive
0.16
Negative
0.25
Negative
Market Momentum
>-0.01
Negative
55.75
Neutral
57.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IMU, the sentiment is Positive. The current price of 0.33 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.11, and above the 200-day MA of 0.25, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 55.75 is Neutral, neither overbought nor oversold. The STOCH value of 57.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:IMU.
Imugene Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | AU$4.86B | -451.47 | -1.72% | ― | 59.13% | -121.52% | |
52 Neutral | AU$71.50M | -7.81 | -62.49% | ― | ― | -13.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$23.66M | -4.10 | 2509.60% | ― | ― | -137.97% | |
44 Neutral | AU$816.81M | -8.32 | -59.59% | ― | ― | -70.72% | |
41 Neutral | AU$39.50M | -0.50 | -134.65% | ― | ― | 62.72% | |
40 Underperform | AU$72.21M | -0.86 | -69.20% | ― | ― | -73.11% |
* Healthcare Sector Average
AU:IMU
Imugene
0.12
-0.36
-75.84%
AU:IMM
Immutep Ltd
0.05
-0.18
-77.45%
AU:PTX
Prescient Therapeutics Limited
0.07
0.02
36.00%
AU:TLX
Telix Pharmaceuticals
14.50
-10.42
-41.81%
AU:NOX
Noxopharm Ltd.
0.07
0.01
21.67%
AU:CU6
Clarity Pharmaceuticals Ltd.
2.17
0.09
4.33%
Imugene Corporate Events
Imugene Wins FDA Fast Track for Off-the-Shelf CAR T in CLL/SLL and MZL
Jun 9, 2026
Imugene has secured U.S. FDA Fast Track Designation for its off-the-shelf CD19-directed CAR T therapy azer-cel in two blood cancer indications, relapsed or refractory CLL/SLL and MZL. The status enables more frequent FDA engagement, rolling review...
Imugene Grants New Unquoted Equity Awards Under Employee Incentive Plan
Jun 2, 2026
Imugene Limited has issued 6,398,773 restricted stock units and 1,676,453 performance rights awards under its employee incentive scheme, with an issue date of 27 May 2026. The unquoted equity awards, which are not intended to be listed on the ASX,...
Imugene Expands Azer-cel Trial With BTK Inhibitor Combo Cohort
May 27, 2026
Imugene has dosed the first patient in a new Bruton Tyrosine Kinase inhibitor combination cohort within its Phase 1b basket study of azer-cel, an allogeneic CAR T cell therapy, at Baylor University in Texas. The trial targets patients with advance...
Imugene bolsters board with seasoned biotech leaders after remuneration strike
May 26, 2026
Imugene has moved to strengthen its board by appointing two new non-executive directors, pharmaceutical physician and biopharma veteran Dr Charmaine Gittleson and experienced pharma operator Michael Kotsanis, effective 30 June 2026. Their combined...
Imugene’s Off-the-Shelf CAR T Azer-cel Delivers 81% Response Rate in Early ASCO Data
May 22, 2026
Imugene has reported promising Phase 1b data for azer-cel, its allogeneic CD19 CAR T-cell therapy, in a CAR T-naïve cohort of patients with relapsed or refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia. The ASCO 2026 abstract s...
Precision BioSciences exits substantial shareholder role in Imugene
May 11, 2026
Imugene Limited has disclosed that U.S.-based Precision BioSciences, Inc. has ceased to be a substantial shareholder in the company following a series of on-market share sales and dilution from a placement. Precision BioSciences reduced its holdin...
Imugene Seeks ASX Quotation for 89 Million New Options
May 4, 2026
Imugene Limited has applied to the ASX for quotation of 89,175,565 new options, carrying the code IMUOF and expiring on 30 April 2027. The options, issued on 1 May 2026 following prior placement disclosures in March, expand the company’s lis...
Imugene Restructures Convertible Notes and Raises New Capital for Oncology Trials
May 1, 2026
Imugene has entered into an amended and restated subscription agreement with an affiliate of Heights Capital Management, part of Susquehanna International Group, to issue $11.2 million in new SAR convertible notes and 66,576,087 unlisted warrants,...
Imugene Cancels 175 Convertible Notes by Mutual Agreement
May 1, 2026
Imugene Limited has announced the cessation of 175 IMUAAR convertible notes, which were cancelled by mutual agreement between the company and the noteholder effective 30 April 2026. The move slightly reduces Imugene’s issued capital in this ...
Imugene Seeks ASX Quotation for 12.5 Million New Shares
May 1, 2026
Imugene Limited has applied to the ASX for quotation of 12,508,898 new ordinary fully paid shares, with an issue date of 30 April 2026. The securities form part of a transaction previously notified to the market, signalling a modest expansion of t...
Imugene plans warrant and convertible note issue to fund growth
Apr 30, 2026
Imugene Limited has outlined a new capital raising move via a proposed issue of securities on the ASX, signaling its ongoing need to fund development activities in immuno‑oncology. The company remains focused on leveraging the equity and deb...
Imugene Seeks ASX Quotation for 31.2 Million New Shares
Apr 30, 2026
Imugene Limited has applied for quotation on the ASX of 31,220,668 new ordinary fully paid shares, with an issue date of 30 April 2026, under its existing ticker IMU. The newly issued securities form part of a previously announced transaction, ind...
Imugene Posts Strong Azer-cel Data and Bolsters Balance Sheet in March Quarter
Apr 30, 2026
Imugene reported strong clinical progress in the March 2026 quarter, highlighted by positive Phase 1b results for its lead CAR T therapy azer-cel in CAR T-naive patients. The trial showed a 100% overall response rate in CLL/SLL and 80% in MZL, and...
Imugene Reveals Dispersed Ownership Across 2027 Listed Options
Apr 29, 2026
Imugene has released a top holders report for its listed options series IMUOPT41, which are exercisable at $0.18 and expire on 30 April 2027, showing a diverse register dominated by nominee and custodial entities. Citicorp Nominees is the largest ...
Imugene Seeks ASX Quotation for New Tranche of 2027 Options
Apr 29, 2026
Imugene Limited has applied to the ASX for quotation of a new class of options, comprising 15,077,309 quoted options exercisable at $0.18 and expiring on 30 April 2027, issued on 24 April 2026. The move adds a significant tranche of listed derivat...
Imugene Seeks ASX Quotation for 15 Million New Shares
Apr 24, 2026
Imugene Limited has applied to the ASX for quotation of 15,077,309 new ordinary fully paid shares, with an issue date of April 24, 2026. The securities form part of a previously announced transaction, indicating an expansion of the company’s...
Imugene Secures $16m Funding as Shareholders Back Capital Raising
Apr 23, 2026
Imugene Limited has secured strong shareholder backing at its Extraordinary General Meeting, with all resolutions passed by poll, clearing the way for completion of its latest capital-raising initiatives. The approvals cover tranche two of an inst...
Imugene CEO Leslie Chong Increases Direct Shareholding via On-Market Purchase
Apr 22, 2026
Imugene chief executive Leslie Chong has increased her direct holding in the company, acquiring 65,053 ordinary fully paid shares on market at A$0.145 per share. Following the transaction, her direct stake has risen to 2,683,835 shares, while her ...
Imugene Cuts Potential Dilution as Expired Options and Rights Lapse
Apr 10, 2026
Imugene Limited has notified the market of the cessation of several classes of equity-linked securities, including more than 5.8 million options expiring on 31 March 2026 that lapsed unexercised. Additional options and restricted stock units, tota...
Imugene applies for ASX quotation of additional ordinary shares
Apr 8, 2026
Imugene Limited has applied to the ASX for quotation of 17,829 new ordinary fully paid shares, to be issued on 11 January 2026 following the conversion or exercise of existing options or other convertible securities. The modest increase in quoted ...
Imugene Issues Additional Unquoted Options as Part of Ongoing Capital Management
Apr 2, 2026
Imugene Limited has notified the market of the issue of a small tranche of unquoted options, with 4,544 IMUAJ options expiring on 30 June 2028 and exercisable at $0.86 being issued on 26 and 30 March 2026. These options form part of previously ann...
Imugene Seeks ASX Quotation for Shares Issued on Option Conversions
Apr 1, 2026
Imugene Limited has applied to the ASX for quotation of new fully paid ordinary shares that have been issued following the exercise of options or conversion of other convertible securities. The newly issued securities, dated 26 March 2026 and 30 M...
Imugene’s Lead CAR T Therapy Azer-cel Wins Prestigious ASCO 2026 Oral Slot
Apr 1, 2026
Imugene announced that new data from its lead CAR T program, azer-cel, has been selected for an oral presentation at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, the world’s premier oncology conference. The compe...
Imugene calls hybrid Extraordinary General Meeting with expanded online access
Mar 22, 2026
Imugene Limited has called an Extraordinary General Meeting to be held on 23 April 2026 at 9:00 a.m. Sydney time, offering both a physical venue in Sydney and a virtual option via the Automic online platform. The company is encouraging shareholder...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.